Myriad Genetics Inc (NASDAQ: MYGN) has reported E.P.S. of $-0.41 for its second fiscal quarter (ending June 30) versus $-1.42 for the same period a year ago. Relative to the consensus estimate of $-0.01, this was a shortfall of $-0.40. For the latest four quarters through June 30, E.P.S. were $-1.80 compared to $-3.05 a year ago.
Recent Price Action
On 8/6/24, Myriad Genetics Inc (NASDAQ: MYGN) stock rose modestly by 0.5%, closing at $25.96. Moreover, trading volume in this advance was unusually high at 170% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -5.0% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, MYGN is expected to continue to be a modest Value Builder.
Myriad Genetics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Myriad Genetics has a very low Appreciation Score of 10 but a good Power Rating of 71, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment